Lyra Therapeutics Stock Performance
| LYRA Stock | USD 0.21 0.02 10.53% |
The company secures a Beta (Market Risk) of 1.36, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lyra Therapeutics will likely underperform. At this point, Lyra Therapeutics has a negative expected return of -0.33%. Please make sure to verify Lyra Therapeutics' skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Lyra Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Acquisition by Merrifield C Ann of 3500 shares of Lyra Therapeutics at 4.813 subject to Rule 16b-3 | 09/10/2024 |
2 | Lyra Therapeutics, Inc. Given Average Rating of Hold by Analysts | 09/16/2024 |
3 | Lyra Therapeutics stock plunges to 52-week low of 0.24 - Investing.com | 10/03/2024 |
4 | Acquisition by Jason Cavalier of 100000 shares of Lyra Therapeutics subject to Rule 16b-3 | 10/16/2024 |
5 | Lyra Therapeutics, Inc. Short Interest Down 24.9 percent in October | 10/30/2024 |
6 | Lyra Therapeutics Inc Q3 2024 Earnings Net Loss of 11.9M, Misses EPS and Revenue Estimates | 11/12/2024 |
| Begin Period Cash Flow | 33.9 M |
Lyra |
Lyra Therapeutics Relative Risk vs. Return Landscape
If you would invest 30.00 in Lyra Therapeutics on September 2, 2024 and sell it today you would lose (9.00) from holding Lyra Therapeutics or give up 30.0% of portfolio value over 90 days. Lyra Therapeutics is currently does not generate positive expected returns and assumes 6.5484% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Lyra, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lyra Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lyra Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lyra Therapeutics, and traders can use it to determine the average amount a Lyra Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0507
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LYRA |
Estimated Market Risk
| 6.55 actual daily | 58 58% of assets are less volatile |
Expected Return
| -0.33 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lyra Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lyra Therapeutics by adding Lyra Therapeutics to a well-diversified portfolio.
Lyra Therapeutics Fundamentals Growth
Lyra Stock prices reflect investors' perceptions of the future prospects and financial health of Lyra Therapeutics, and Lyra Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lyra Stock performance.
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.42 | ||||
| Operating Margin | (49.43) % | ||||
| Current Valuation | (2.74 M) | ||||
| Shares Outstanding | 65.46 M | ||||
| Price To Book | 0.66 X | ||||
| Price To Sales | 9.22 X | ||||
| Revenue | 1.56 M | ||||
| Gross Profit | (34.23 M) | ||||
| EBITDA | (65.25 M) | ||||
| Net Income | (62.68 M) | ||||
| Cash And Equivalents | 120.67 M | ||||
| Cash Per Share | 3.79 X | ||||
| Total Debt | 26.88 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.40 X | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (63.3 M) | ||||
| Earnings Per Share | (1.49) X | ||||
| Market Capitalization | 13.56 M | ||||
| Total Asset | 142.6 M | ||||
| Retained Earnings | (311.36 M) | ||||
| Working Capital | 85.22 M | ||||
| Current Asset | 12.7 M | ||||
| Current Liabilities | 4.82 M | ||||
About Lyra Therapeutics Performance
By analyzing Lyra Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Lyra Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lyra Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lyra Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.55) | (0.57) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.70) | (0.74) |
Things to note about Lyra Therapeutics performance evaluation
Checking the ongoing alerts about Lyra Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lyra Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lyra Therapeutics generated a negative expected return over the last 90 days | |
| Lyra Therapeutics has high historical volatility and very poor performance | |
| Lyra Therapeutics has some characteristics of a very speculative penny stock | |
| Lyra Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.56 M. Net Loss for the year was (62.68 M) with loss before overhead, payroll, taxes, and interest of (34.23 M). | |
| Lyra Therapeutics currently holds about 120.67 M in cash with (63.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 60.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Lyra Therapeutics Inc Q3 2024 Earnings Net Loss of 11.9M, Misses EPS and Revenue Estimates |
- Analyzing Lyra Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lyra Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Lyra Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lyra Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lyra Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lyra Therapeutics' stock. These opinions can provide insight into Lyra Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lyra Stock analysis
When running Lyra Therapeutics' price analysis, check to measure Lyra Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lyra Therapeutics is operating at the current time. Most of Lyra Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lyra Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lyra Therapeutics' price. Additionally, you may evaluate how the addition of Lyra Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |